[go: up one dir, main page]

BR112018003212A2 - diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3 - Google Patents

diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3

Info

Publication number
BR112018003212A2
BR112018003212A2 BR112018003212A BR112018003212A BR112018003212A2 BR 112018003212 A2 BR112018003212 A2 BR 112018003212A2 BR 112018003212 A BR112018003212 A BR 112018003212A BR 112018003212 A BR112018003212 A BR 112018003212A BR 112018003212 A2 BR112018003212 A2 BR 112018003212A2
Authority
BR
Brazil
Prior art keywords
expression
nlrp3
diacerein
asc
analogues
Prior art date
Application number
BR112018003212A
Other languages
English (en)
Inventor
Oscar Brown Carl Iii
Chen Chih-Kuang
Lee Jing-Yi
Lu Wei-Shu
Original Assignee
Twi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twi Biotechnology Inc filed Critical Twi Biotechnology Inc
Publication of BR112018003212A2 publication Critical patent/BR112018003212A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

são proporcionados métodos e composições para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo de inflamasoma nlrp3 utilizando diacereína ou seus análogos. também são fornecidos métodos e composições para o tratamento e / ou prevenção de uma doença mediada por asc e / ou nlrp3 e / ou por formação de complexo de inflamassoma nlrp3 usando diacereína ou seus análogos.
BR112018003212A 2015-08-17 2016-08-17 diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3 BR112018003212A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206102P 2015-08-17 2015-08-17
PCT/US2016/047272 WO2017031161A1 (en) 2015-08-17 2016-08-17 Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex

Publications (1)

Publication Number Publication Date
BR112018003212A2 true BR112018003212A2 (pt) 2018-09-25

Family

ID=58051269

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003212A BR112018003212A2 (pt) 2015-08-17 2016-08-17 diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3

Country Status (14)

Country Link
US (1) US10195170B2 (pt)
EP (2) EP3337782A4 (pt)
JP (3) JP6887987B2 (pt)
KR (1) KR20180037261A (pt)
CN (1) CN108349867B (pt)
AU (2) AU2016308121A1 (pt)
BR (1) BR112018003212A2 (pt)
CA (1) CA2994987C (pt)
HK (1) HK1254388A1 (pt)
IL (1) IL257379A (pt)
MX (1) MX2018002049A (pt)
RU (1) RU2729066C2 (pt)
TW (1) TWI743047B (pt)
WO (1) WO2017031161A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017386550A1 (en) 2016-12-29 2019-08-08 University Of Miami Method for modulating inflammasome activity and inflammation in the lung
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
AU2018210771B2 (en) 2017-01-18 2020-04-02 Tairx, Inc. Compositions for use in treating inflammatory bowel diseases and intestinal colitis
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
EP3664786B1 (en) * 2017-08-11 2022-10-05 Olatec Therapeutics LLC Method for treating schnitzler's syndrome
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
KR102075724B1 (ko) * 2018-09-14 2020-02-10 한국원자력의학원 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도
EP3876712B1 (en) 2018-11-14 2024-02-14 Smilebiotek Zhuhai Limited Screening methods for treatments of intraocular diseases or disorders
FI3886852T3 (fi) * 2018-12-03 2024-04-29 Smilebiotek Zhuhai Ltd Oktyyligallaatti ja sen estereitä käytettäväksi Bacillus megateriumin aiheuttaman ikään liittyvän silmänpohjan rappeuman hoidossa ja ehkäisyssä
US12084416B2 (en) 2019-01-14 2024-09-10 Zydus Lifesciences Limited Substituted sulfonylurea derivatives
CN109833292A (zh) * 2019-02-23 2019-06-04 河南省人民医院 一种双醋瑞因滴眼液及其用途
WO2020212484A1 (en) 2019-04-17 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN110179865A (zh) * 2019-06-26 2019-08-30 广州中医药大学(广州中医药研究院) 一种大黄蒽醌类成分的制备方法及其应用
CN110787157A (zh) * 2019-11-27 2020-02-14 中南民族大学 双醋瑞因在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用
JP7072260B2 (ja) * 2019-12-27 2022-05-20 国立大学法人愛媛大学 マックル・ウェルズ症候群の治療用医薬組成物
CA3163848A1 (en) * 2020-01-06 2021-07-15 Dong In Lee Composition for preventing or treating macular degeneration, containing cell permeable nucleic acid complex as active ingredient
CN111358950A (zh) * 2020-03-20 2020-07-03 厦门大学 Caspase-1及ASC/Caspase-8作为靶点的应用
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2022084300A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring form of coronavirus infection
CN115616216A (zh) * 2021-07-15 2023-01-17 华南理工大学 抑制或阻断faah与nlrp3之间相互作用的制剂的用途
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128317A1 (en) * 2001-01-23 2002-09-12 Laboratories Negma Treatment of pathological conditions characterized by an increased IL-1 level
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
GB0404953D0 (en) * 2004-03-04 2004-04-07 Arakis Ltd Pro-drugs
CA2729780A1 (en) 2008-07-03 2010-01-07 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
CN102060809B (zh) * 2009-05-01 2015-05-20 常州高新技术产业开发区三维工业技术研究所有限公司 一种大黄酸衍生物及其制备和用途
BR112012024936A2 (pt) * 2010-04-08 2015-09-15 Twi Biotechnology Inc uso de diacereína ou de um sal, um análogo, uma prodroga, ou um metabólito ativo farmaceuticamente aceitável do mesmo
US20140163217A1 (en) * 2010-07-29 2014-06-12 Universite De Geneve Process for the esterification of hyaluronic acid with hydrophobic organic compounds
CN103429236B (zh) 2011-03-11 2016-09-21 安成生物科技股份有限公司 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物
US9707272B2 (en) 2011-07-12 2017-07-18 Universitat Zurich Method for the treatment of acne by administering IL-1β antibody
US8652540B2 (en) * 2012-06-04 2014-02-18 Hong Kong Baptist University Method of using rhein for treating fibrotic conditions and tumors
CN103110617A (zh) * 2013-03-22 2013-05-22 中国人民解放军肾脏病研究所 一种双醋瑞因在制备治疗糖尿病肾病药物中的用途
KR101486147B1 (ko) * 2013-07-09 2015-01-23 주식회사 엘지생활건강 Tslp 분비 저해능 및 이에 의한 알러지성 질환의 개선능을 가지는 조성물
KR102702557B1 (ko) * 2015-07-01 2024-09-03 티더블유아이 바이오테크놀로지 인코포레이티드 디아세레인 또는 레인 국소 제형 및 이의 용도

Also Published As

Publication number Publication date
JP6887987B2 (ja) 2021-06-16
US20170049733A1 (en) 2017-02-23
AU2021200117A1 (en) 2021-03-18
EP3337782A4 (en) 2019-04-03
US10195170B2 (en) 2019-02-05
TWI743047B (zh) 2021-10-21
WO2017031161A1 (en) 2017-02-23
MX2018002049A (es) 2018-06-15
JP2018523687A (ja) 2018-08-23
AU2021200117B2 (en) 2023-09-28
IL257379A (en) 2018-04-30
EP3337782A1 (en) 2018-06-27
RU2018109237A3 (pt) 2019-12-31
JP2023078360A (ja) 2023-06-06
CN108349867A (zh) 2018-07-31
JP2021121605A (ja) 2021-08-26
TW201717927A (zh) 2017-06-01
CA2994987C (en) 2023-09-26
EP4147694A1 (en) 2023-03-15
HK1254388A1 (zh) 2019-07-19
KR20180037261A (ko) 2018-04-11
RU2018109237A (ru) 2019-09-19
CA2994987A1 (en) 2017-02-23
CN108349867B (zh) 2021-03-09
AU2016308121A1 (en) 2018-03-01
RU2729066C2 (ru) 2020-08-04

Similar Documents

Publication Publication Date Title
BR112018003212A2 (pt) diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
PH12017500583B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
CR20180374A (es) Compuestos heterocíclicos como inmunomoduladores
MX2017011037A (es) Bacteria manejada geneticamente para tratar enfermedades que se benefician de inflamacion intestinal reducida y/o barrera mucosa intestinal fortalecida.
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
GT201700107A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112017004704A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
EA201891251A1 (ru) Бициклические ингибиторы pad4
MX375706B (es) Compuestos de inhibidor de autotaxina.
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
BR112015030203A2 (pt) moléculas pequenas inibidores da fibrose
MX389449B (es) Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
ECSP14030779A (es) Inhibidores del nampt
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
CO2017002813A2 (es) Derivados estabilizados de adrenomedulina y uso de los mismos

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements